1198090-71-9

Usage

Uses

Used in Pharmaceutical Industry:
4-(oxiran-2-ylmethoxy)-9-(oxiran-2-ylmethyl)-9H-carbazole is used as an intermediate in the synthesis of N-2-Hydroxy-3-[[2-(methoxyphenoxy)ethyl]amine Carvedilol (Carvedilol EP Impurity A) (H946145), which is an impurity from the process of Carvedilol (C184625). This intermediate plays a crucial role in the development and production of Carvedilol, a medication used to treat heart failure, hypertension, and other cardiovascular conditions.

Upstream product

• 52602-39-8 9H-carbazol-4-ol 
• 106-89-8 epichlorohydrin 
• 51997-51-4 4-(2,3-epoxypropoxy)carbazole 

Downstream Products

• 1198090-73-1 1-(4-(2-hydroxy-3-(2-(2-methoxyphenoxy)ethylamino)propoxy)-9H-carbazol-9-yl)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol 
• 1198090-72-0 1-(benzyl(2-(2-methoxyphenoxy)ethyl)amino)-3-(4-(3-(benzyl(2-(2-methoxyphenoxy)ethyl)amino)-2-hydroxypropoxy)-9H-carbazol-9-yl)propan-2-ol 

Relevant academic research and scientific papers

Synthesis and characterization of potential impurities of carvedilol, an antihypertensive drug

Carvedilol (Coreg) is a nonselective -adrenergic blocking agent with vasodilating activity. It is used for the treatment of congestive heart failure and hypertension. During the bulk synthesis of carvedilol, we have observed six impurities: Imp-I, Imp-II, Imp-III, Imp-IV, Imp-V, and Imp-VI. The present work describes the synthesis and characterization of these impurities. Copyright

Synthesis of impurity A in Carvedilol: a β-adrenergic receptor

Carvedilol is prepared by different synthetic approaches. Almost in all the approaches the major impurities that are known in the literature A, B, C, D and E are listed in European pharmacopoeia. The control of pharmaceutical impurities is currently a critical issue to the pharmaceutical industry. In this publication, a description of these impurities and their origins in Carvedilol process are presented along with the preparation of impurity A.